Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLOPAR vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Acne vulgaris,Brucellosis,Cholera,Granuloma inguinale,Listeriosis,Lymphogranuloma venereum,Mycoplasma pneumoniae infection,Psittacosis,Q fever,Rocky Mountain spotted fever,Syphilis (when penicillin contraindicated),Trachoma,Tularemia,Urinary tract infections (caused by susceptible organisms)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
500 mg orally twice daily for 7-14 days.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
4-6 hours in normal renal function; prolonged to 12-24 hours in moderate impairment; up to 48 hours in severe impairment
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Tetracycline is not extensively metabolized; primarily excreted unchanged in urine and feces.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal (80-90% unchanged), fecal (10-20%)
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
25-30% bound to albumin
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.2-0.3 L/kg (suggests low tissue penetration; primarily extracellular fluid)
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 60-75%; IM: ~100%
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl 30-50 m L/min: 500 mg once daily; Cr Cl 15-29 m L/min: 250 mg once daily; Cr Cl <15 m L/min or on dialysis: 250 mg every 48 hours.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No adjustment required for mild to moderate impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): use with caution; consider reduced dose.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
For children >1 year: 15 mg/kg/day divided every 12 hours, not to exceed 500 mg per dose.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific dose adjustment based on age alone; dose based on renal function. Use minimum effective dose and monitor renal function.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Tetracycline use during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Photosensitivity: exaggerated sunburn reaction may occur.,Hepatotoxicity: rare but can occur, especially in patients with renal impairment.,Renal impairment: may require dose adjustment; avoid in severe renal dysfunction.,Pseudomembranous colitis: Clostridium difficile-associated diarrhea may occur.,Superinfection: overgrowth of nonsusceptible organisms including fungi.,Use in pregnancy: category D; avoid due to risk to fetus.,Use in children <8 years: avoid due to tooth discoloration and bone growth inhibition.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to tetracycline or any component,Pregnancy (last half),Children under 8 years,Severe hepatic or renal impairment
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid dairy products (milk, yogurt, cheese), calcium-fortified foods, and antacids containing calcium, magnesium, or aluminum within 2 hours of taking cyclopar. Iron supplements, zinc, and bismuth subsalicylate also reduce absorption. Take with a full glass of water; avoid concurrent intake of high-iron foods (e.g., spinach, red meat) within 1-2 hours. No significant interaction with alcohol but caution due to potential hepatotoxicity.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Cyclopar (tetracycline) is classified as FDA Pregnancy Category D. Use is contraindicated in the second and third trimesters due to risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Additionally, tetracyclines can cause reversible inhibition of fetal bone growth. Avoid during pregnancy; alternative antibiotics should be selected.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Tetracyclines are excreted into breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.5–1.5. Theoretical risks include dental staining and bone growth inhibition in the nursing infant. However, due to poor oral absorption and binding to milk calcium, systemic exposure is minimal. Use is generally considered compatible with breastfeeding if short-term; caution is advised with prolonged therapy.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No pharmacokinetic data specifically for pregnancy; standard adult dosing may be used if absolutely necessary, but use is discouraged. If unavoidable, monitor serum levels (therapeutic range 5–10 mcg/m L) as pregnancy-induced changes in volume of distribution and renal clearance may alter drug exposure. Dose adjustments should be guided by clinical response and serum levels.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Cyclopar (tetracycline) should be taken on an empty stomach 1 hour before or 2 hours after meals to enhance absorption. Avoid concurrent use with dairy products, antacids, or iron supplements due to chelation. Photosensitivity is common; advise sun protection. Monitor for superinfection, especially C. difficile colitis. Use with caution in renal impairment; adjust dose to avoid nephrotoxicity. Not recommended in children under 8 years or during pregnancy due to bone and teeth discoloration.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take this medication on an empty stomach with a full glass of water, at least 1 hour before or 2 hours after meals.,Avoid dairy products, antacids, iron supplements, and calcium-rich foods for at least 2 hours before and after taking this drug.,This drug can make your skin more sensitive to sunlight; use sunscreen, wear protective clothing, and avoid tanning beds.,Complete the full course of treatment even if you feel better; do not skip doses.,Inform your doctor if you experience severe diarrhea, vaginal itching, or oral thrush as these may indicate a secondary infection.,Do not use this medication if you are pregnant, planning to become pregnant, or breastfeeding without consulting your doctor.,Store at room temperature away from moisture and heat. Do not use outdated tetracycline as it can become toxic.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLOPAR vs ABSTRAL, answered by our medical review team.
CYCLOPAR is a Muscle Relaxant that works by Cyclopar (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLOPAR and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLOPAR is: 500 mg orally twice daily for 7-14 days.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLOPAR and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLOPAR is classified as Category C. Cyclopar (tetracycline) is classified as FDA Pregnancy Category D. Use is contraindicated in the second and third trimesters due to risk of permanent tooth discoloration (yellow-gr. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.